Exclusive: Immunotherapy developer Dynavax explores options for Hepatitis B drug-sourcesReuters(Reuters) – Dynavax Technologies Corporation, a biotechnology company focused on drugs that harness the immune system to combat disease, is reviewing strateg… Continue reading
Exclusive: Immunotherapy developer Dynavax explores options for Hepatitis B drug-sourcesReuters(Reuters) – Dynavax Technologies Corporation, a biotechnology company focused on drugs that harness the immune system to combat disease, is reviewing strateg… Continue reading
Exclusive: Immunotherapy developer Dynavax explores options for Hepatitis B drug-sourcesReuters(Reuters) – Dynavax Technologies Corporation, a biotechnology company focused on drugs that harness the immune system to combat disease, is reviewing strateg… Continue reading
wtkr.com |
Teen first in Virginia to receive cancer gene therapy in UVA clinical trial
wtkr.com CHARLOTTESVILLE, Va. – A teenager in Virginia becomes the first in the state to receive cancer gene therapy through a University of Virginia Health System clinical trial. The approach, known as chimeric antigen receptor (CAR) T-cell therapy, takes a … |
Fred Hutch News Service |
Good News at Fred Hutch
Fred Hutch News Service Gene therapy has the potential to change how we treat diseases such as cancer and HIV, but it’s only available in high-tech clean rooms. Why isn’t it more widely available? “It’s complicated and expensive,” said Dr. Jennifer Adair during her recent … |
|
Guest commentary: Early trials support use of CAR T-cell therapy in glioblastoma
Healio What’s pretty remarkable about that trial is that they had a patient who experienced complete regression of multiple lesions after several infusions of the CAR T cells; they published that data last year. An open trial at Baylor is using CAR T cells to … |